LOS ANGELES, CA - (NewMediaWire) - March 27, 2023 - On March 3, 2023, US Nuclear Corp (UCLE) sold its interest in Cali from Above, a private company engaged in the business of UAV/drone sales and drone services, located in Canoga Park, California to its President and Chief Executive Officer, Robert Goldstein, in consideration of UCLE receiving 65,000,000 shares of common stock in Averox, Inc. (OTC: AVRI) resulting in UCLE owning approximately 26% of issued and outstanding shares of common stock in AVRI. Mr. Goldstein commented, “We believe that Cali from Above has high potential and can better serve the fast-growing drone industry in a separate public company.” Simultaneous with the closing of this agreement, Mr. Goldstein sold his interests in Cali from Above to AVRI as part of the restructuring. USN and Cali from Above have also signed a Cooperation Agreement giving USN exclusive sourcing and manufacturing rights for Cali products, thus making Cali a new USN customer.
Previously, Averox had been primarily a software development company. Now Averox’s goal is to become a leader in important growth industries.
About Cali from Above:
CALI specializes in buying and selling drones, also affixing drone accessories and drone payloads. Also pilot training, drone inspection of wind turbines, solar panels, construction jobs, and many other purposes or missions.
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.